Investment Thesis
Janux Therapeutics exhibits severely negative unit economics with $3.7M revenue generating $24.4M net losses, signaling minimal commercial traction and unsustainable cash burn of $12.3M quarterly despite early-stage pharma status. While the balance sheet provides a 2-3 year cash runway ($51.8M), deteriorating profitability (net income down 64.7% YoY) and negative free cash flow (-$337.8% FCF margin) indicate shareholder value destruction accelerating at an alarming pace.
Strengths
- Fortress balance sheet with $941.5M stockholders' equity and zero long-term debt
- Exceptional liquidity position (17.01x current ratio) providing operational runway
- Low leverage (0.00x debt-to-equity) with minimal near-term refinancing risk
Risks
- Accelerating losses with net income declining 64.7% YoY despite nominal revenue base
- Severe cash burn of $12.3M operating outflow quarters unsustainable without revenue inflection
- Minimal revenue generation ($3.7M) with negative 5.6% YoY trend suggesting market adoption failure
- Operating margin of -916.5% indicates business model fundamentally broken at current stage
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining runway given current equity burn
- Revenue growth trajectory and clinical pipeline advancement toward commercialization
- Gross margin and unit economics upon achieving meaningful revenue scale
Financial Metrics
Revenue
3.7M
Net Income
-24.4M
EPS (Diluted)
$-0.39
Free Cash Flow
-12.6M
Total Assets
1.0B
Cash
51.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-916.5%
Net Margin
-652.6%
ROE
-2.6%
ROA
-2.4%
FCF Margin
-337.8%
Balance Sheet & Liquidity
Current Ratio
17.01x
Quick Ratio
17.01x
Debt/Equity
0.00x
Debt/Assets
8.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:28:51.611351 |
Data as of: 2026-03-31 |
Powered by Claude AI